SentinelOne Named a Leader in the 2021 Gartner Magic Quadrant for Endpoint Protection Platforms
10.5.2021 19:12:00 EEST | Business Wire | Press release
SentinelOne, the autonomous cybersecurity platform company, today announced it has been positioned by Gartner as a Leader in the 2021 Magic Quadrant for Endpoint Protection Platforms1. SentinelOne believes the placement is a testament to the company’s innovative Singularity XDR platform and scaled go-to-market execution in record time. We believe this accomplishment signifies unrivaled product-market fit, innovation, and superb customer experience across a diverse set of customer profiles.
“Modern society is digital, and every place where data resides is vulnerable. Human-powered products simply cannot keep up with the exponentially growing threat landscape. Our AI-powered technology is the automated solution to modern day cyberattacks,” said Tomer Weingarten, CEO and Co-founder, SentinelOne. “We believe being named a Leader in the Gartner Magic Quadrant validates our approach and aligns with the market traction we’re experiencing. I am proud our team continues to deliver innovation, scale, and growth – all while keeping our customers protected.”
“SentinelOne is experiencing hypergrowth new logo adoption as well as module expansion from our existing customer base,” said Nicholas Warner, COO, SentinelOne. “We continue to outperform next-gen and legacy EPP vendors around the globe in comparative evaluations, demonstrating our ability to address cybersecurity at the pace and scale needed by modern businesses of all sizes to defeat attacks at machine speed.”
With excellent scores across EDR, EPP, and MDR in Gartner Peer Reviews, SentinelOne continues to deliver best-in-class customer satisfaction to its rapidly expanding global customer base of leading enterprises. In addition to being named a Leader in this year’s Magic Quadrant, SentinelOne received the highest overall rating and most verified reviews for the overall rating category in the 2020 Gartner Peer Insights ‘Voice of the Customer’: Endpoint Detection and Response Solutions report, and was recognized as a November 2019 Gartner Peer Insights Customers’ Choice for Endpoint Protection Platforms.
Gartner Peer Insights documents customer experience through verified ratings and peer reviews from enterprise IT professionals. As of April 23, 2021, SentinelOne reviews include the following:
“SentinelOne is a pioneering solution in endpoint protection with a rapid development lifecycle, best-of-breed platform support, and an unrivaled API.” - Information Security Manager, Manufacturing [read full review]
“SentinelOne has become a main piece of our security portfolio. It was deployed to the majority of workstations and servers in our environment nearly overnight.” - Sr. Cybersecurity Analyst, Miscellaneous [read full review]
“We looked at Cylance, Crowdstrike, Microsoft ATP Defender, Carbon Black and SentinelOne. Overall, S1 is an absolute game changer. These guys are disrupting traditional cyber security in a big way and will leave every CISO and their organization with little doubt about the right choice of EDR product.” - Senior Director, Cyber Security, Retail [read full review]
“We couldn't be happier with SentinelOne! We did our own lab comparison of 11 products. SentinelOne came out on top easily!" [read full review]
“SentinelOne has been critical in protecting our business. This platform provides not only next-gen AV, but also EDR. We actually made the decision to not renew our existing EDR platform because of SentinelOne's advanced EDR features.” - VP -- Detection and Response, Finance [read full review]
- To register for our upcoming webinar on Wednesday, May 19th at 10:00 AM PDT, please visit: LINK
- Download a complimentary copy of the 2021 Gartner Magic Quadrant for Endpoint Protection platforms by visiting: LINK
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner Peer Insights reviews constitute the subjective opinions of individual end users based on their own experiences and do not represent the views of Gartner or its affiliates.
Gartner Peer Insights Customers’ Choice constitute the subjective opinions of individual end-user reviews, ratings, and data applied against a documented methodology; they neither represent the views of, nor constitute an endorsement by, Gartner or its affiliates.
About SentinelOne
SentinelOne is the leading cybersecurity solution encompassing AI-powered prevention, detection, response and hunting across endpoints, containers, cloud workloads, and IoT devices in a single autonomous platform. With SentinelOne, organizations gain transparency into everything happening across the network at machine speed – to defeat attacks, at every stage of the threat lifecycle. To learn more visit www.sentinelone.com or follow us at @SentinelOne, on LinkedIn or Facebook.
1 Gartner, Magic Quadrant for Endpoint Protection Platforms, Paul Webber, Peter Firstbrook, Rob Smith, Mark Harris, Prateek Bhajanka, 5 May 2021
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005705/en/
Contact information
Maryellen Sartori
fama PR for SentinelOne
P: 617-986-5035
E: S1@famapr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom